Open AccessSerum 3-Hydroxybutyrate in Patients with Psychogenic Somatoform Symptoms May Be a Predictor of the Effectiveness of Sertraline and Venlafaxine
Author(s) -
Norihiro Saito,
Masamichi Itoga,
Satoko Minakawa,
Hiroyuki Kayaba
Publication year - 2021
Publication title -
international journal of general medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.722
H-Index - 36
ISSN - 1178-7074
DOI - 10.2147/ijgm.s300517
Subject(s) - sertraline , venlafaxine , psychogenic disease , medicine , odds ratio , suicidal ideation , confidence interval , logistic regression , reuptake inhibitor , psychiatry , gastroenterology , poison control , serotonin , injury prevention , antidepressant , receptor , environmental health , hippocampus
Selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs) are often used to treat outpatients with psychogenic somatoform symptoms but prove ineffective in some cases. The metabolite 3-hydroxybutyrate (3HB) is currently attracting attention as a marker of the severity of depression. We investigated whether serum 3HB levels in patients with psychogenic somatoform symptoms can predict the effectiveness of sertraline and venlafaxine.